T-cell focused TScan Therapeutics have published data identifying the targets of T cells it isolated from Covid-19 patients. TScan used its proprietary identification technology to map the memory CD8+ T cell response of these patients.
The company has now submitted these findings for review with the aim of supporting Covid-19 vaccine development. Long-term immunity from Covid-19 vaccines requires the conferring of both antibody and T cell immunity.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
TScan chief scientific officer Gavin MacBeath explained: “Covid-19 vaccine development efforts have been progressing rapidly, but to date remain largely focused on eliciting a neutralizing antibody response against the virus’ spike protein.
“Because antibodies to SARS-CoV-2 [the virus which causes Covid-19] appear to diminish over time, there is growing concern that if vaccines do not also generate a strong T cell response, they may only provide short-term immunity.
“An increasing body of evidence suggests that the T cell response is important in the defense against Covid-19, and T cells that recognize coronaviruses tend to persist much longer than antibodies.
:In this study, we identified a short list of the most critical T cell targets that could form the basis of a second-generation vaccine, potentially an important follow-on approach to the spike protein vaccines that are currently being developed.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
